How should a 37-year-old man with stage 5 chronic kidney disease (estimated GFR 13 mL/min/1.73 m², BUN 47 mg/dL, serum creatinine 5.30 mg/dL) be managed?

Management of Stage 5 CKD in a 37-Year-Old Male

This patient requires immediate nephrology referral for urgent dialysis planning and comprehensive volume, metabolic, and cardiovascular management—do not delay because conservative management at this GFR is appropriate only in highly selected elderly patients, not a 37-year-old who will likely need decades of renal replacement therapy. 1

---

Immediate Nephrology Referral

• Mandatory nephrology consultation must occur within days for patients with eGFR 13 mL/min/1.73 m² who are not yet on dialysis, to plan urgent vascular or peritoneal access and initiate renal replacement therapy. 1
• Do not wait until eGFR falls below 10 mL/min/1.73 m² or uremic symptoms appear; access creation (arteriovenous fistula or peritoneal catheter) requires several months to mature. 1
• While conservative management can safely prolong dialysis-free survival in elderly patients with stage 5 CKD 2, and some stage 5 patients can remain stable for years 3, a 37-year-old requires proactive planning because he will likely need dialysis for decades and early access placement improves long-term outcomes.

---

Volume Status Assessment and Management

• Assess for volume overload by examining for peripheral edema, ascites, jugular venous distension, and hepatic congestion; if present, initiate urgent hemodialysis with aggressive ultrafiltration to achieve euvolemia. 1
• Target a dry weight that eliminates all signs of volume overload; patients are not stable until euvolemia is reached. 1
• If residual urine output exists, use high-dose loop diuretics (furosemide 80–240 mg IV twice daily or continuous infusion) rather than thiazides, because thiazides are ineffective at eGFR < 30 mL/min/1.73 m². 1
• Expect a modest rise in BUN and creatinine with aggressive diuresis; such elevations should not prompt reduction of diuretic intensity if renal function remains stable. 1
• Limit dietary sodium to < 2 g per day and restrict total fluid intake to < 1.5 L per day if anuric to prevent interdialytic volume accumulation. 1

---

Blood Pressure and Cardiovascular Management

RAAS Inhibition

• Continue or optimize ACE-inhibitor therapy even at eGFR 13 mL/min/1.73 m²; these agents provide cardiovascular benefit and should be maintained as renal function declines below 30 mL/min/1.73 m². 1
• Monitor serum potassium weekly initially because stage 5 CKD patients on ACE inhibitors are at high risk for hyperkalemia. 1
• Do not discontinue ACE inhibitors solely because creatinine rises modestly after volume removal; this reflects hemodynamic changes linked to long-term cardioprotection. 1
• Avoid dual RAAS blockade (combining ACE inhibitor with ARB); this increases hyperkalemia and acute kidney injury risk without added benefit. 1, 4

Additional Antihypertensive Therapy

• If blood pressure remains uncontrolled after volume optimization and ACE-inhibitor therapy, add a dihydropyridine calcium-channel blocker (e.g., amlodipine 5–10 mg daily); no renal dose adjustment is required and efficacy is preserved at all levels of renal function. 1
• Do not initiate beta-blockers in the presence of significant fluid retention, systolic blood pressure < 80 mmHg, or peripheral hypoperfusion. 1
• Beta-blockers become indicated only after euvolemia is achieved and the patient has documented heart failure with reduced ejection fraction, prior myocardial infarction, or active angina. 1

Cardiac Evaluation

• Obtain an urgent transthoracic echocardiogram to assess left ventricular ejection fraction, right-ventricular function, estimated pulmonary artery pressure, valvular abnormalities (especially tricuspid regurgitation), and pericardial effusion (uremic pericarditis). 1
• If heart failure with reduced ejection fraction (LVEF < 40%) is confirmed, beta-blockers become appropriate after euvolemia and hemodynamic stability are achieved. 1

---

Metabolic and Laboratory Monitoring

Hyperkalemia Prevention

• If serum potassium exceeds 5.5 mmol/L, limit dietary potassium to < 2 g/day, avoid salt substitutes, and consider adding a loop diuretic (furosemide 20–40 mg daily) if residual urine output exists. 4
• When hyperkalemia occurs, continue ACE inhibitor and use a potassium binder (e.g., patiromer) rather than stopping the RAAS blocker. 4

Anemia Management

• Diagnose and evaluate anemia according to KDIGO 2026 anemia guidelines; use iron supplementation to treat iron deficiency and consider erythropoiesis-stimulating agents or hypoxia-inducible factor-prolyl hydroxylase inhibitors to treat anemia in CKD. 5

Metabolic Acidosis, Hyperphosphatemia, and Secondary Hyperparathyroidism

• Monitor for and treat metabolic acidosis, hyperphosphatemia, vitamin D deficiency, and secondary hyperparathyroidism, which are common complications at this stage of CKD. 6

Nutritional Support

• Aim for protein intake of 0.8 g/kg/day; if uremic symptoms develop (nausea, pruritus, altered mental status, pericarditis), restrict to 0.6 g/kg/day. 4

---

Medication Adjustments and Nephrotoxin Avoidance

• Avoid NSAIDs absolutely; they are contraindicated at eGFR 13 mL/min/1.73 m² and can precipitate acute renal failure. 4, 6
• Adjust dosing of renally cleared medications (e.g., many antibiotics, oral hypoglycemic agents) according to eGFR. 6
• Review all medications for potential nephrotoxicity and discontinue or substitute when possible. 6

---

Dialysis Modality Planning

• Hemodialysis requires arteriovenous fistula creation now (takes 3–6 months to mature) or tunneled dialysis catheter if urgent initiation is needed. 1
• Peritoneal dialysis may be preferable if the patient desires home-based therapy, has difficult vascular access, or wishes to preserve residual renal function longer. 4
• Discuss both modalities with the patient and nephrology team to determine the best fit for his lifestyle, comorbidities, and preferences.

---

Critical Pitfalls to Avoid

• Do not delay dialysis initiation in symptomatic patients with advanced renal failure and volume overload; transition to maintenance hemodialysis or peritoneal dialysis is often required. 1
• Do not discontinue ACE inhibitors solely because creatinine rises modestly after volume removal; this rise is expected and benign. 1
• Do not use thiazide diuretics at this level of renal function; they are ineffective. 1
• Do not combine ACE inhibitors with ARBs or direct renin inhibitors because it dramatically increases hyperkalemia risk in stage 5 CKD. 1
• Delay in nephrology referral should be avoided; patients with eGFR < 30 mL/min/1.73 m² require specialist co-management. 4

---

Staging and Risk Assessment

• This patient has CKD stage 5 (eGFR < 15 mL/min/1.73 m²), defined by persistent abnormality in kidney structure or function for more than 3 months. 7, 6
• Measure urine albumin-to-creatinine ratio (ACR) to assess risk of CKD progression and guide nephroprotective treatment; ACR ≥ 300 mg/g indicates high risk. 7, 6
• Use the Kidney Failure Risk Equation to estimate the risk of kidney failure and guide clinical decisions. 7